Is Vertex Pharmaceuticals Heading to $600?
Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy few years. The biotech company, known for its leadership in the cystic fibrosis (CF) treatment market, has proven its ability to broaden into other areas -- and win. The company gained approval for blood disorders treatment, Casgevy, and later for non-opioid pain drug, Journavx. And Vertex expanded its CF leadership with a new approval in that area, too.
Just recently, the company delivered more good news to investors: Povetacicept, its candidate for kidney disease IgA nephropathy, met its goals, and the company aims to submit it to regulators by the end of the month.
Considering the good news, is Vertex heading to $600? Let's find out.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
€373.00
-0.290%
With 47 Buy predictions and not a single Sell prediction Vertex Pharmaceuticals Inc. is an absolute favorite of our community.
As a result the target price of 461 € shows a positive potential of 23.59% compared to the current price of 373.0 € for Vertex Pharmaceuticals Inc..
